Figure 3.

Nomograms for (A) recurence of any transitional cell carcinoma; (B) recurrence of grade 3 Ta or T1, or of carcinoma in situ (CIS); (C) recurrence of T2 or higher stage transitional cell carcinoma in 2681 patients who underwent office cystoscopy for detection of bladder cancer recurrence after treatment of stage Ta, T1, and/or CIS urothelial carcinoma of the urinary bladder. Reprinted from The Journal of Urology, Vol. 173, Shariat SF et al, “Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder,” pp. 1518–1525, Copyright American Urological Association 2005.